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A B S T R A C T
Purpose
Cutaneous melanoma incidence is increasing. Most new cases are thin ( 1 mm) with favorable
prognoses, but survival is nonetheless variable. Our aim was to investigate new prognostic factors
and construct a nomogram for predicting survival in individual patients.
Patients and Methods
Data from 2,243 patients with thin melanoma were retrieved from prospectively maintained
databases at six centers. Kaplan-Meier survival and crude cumulative incidences of recurrence
were estimated, and competing risks were taken into account. Multivariable Cox regression was
used to investigate survival predictors.
Results
Median follow-up was 124 months (interquartile range, 106 to 157 months); 12-year overall survival
was 85.3% (95% CI, 83.4% to 87.2%). Median times to local, regional, and distant recurrence were
79, 78, and 107 months, respectively. Relapse was significantly related to age, Breslow thickness,
mitotic rate (MR), ulceration, lymphovascular invasion (LVI), and regression; incidence was lower and
subgroup differences were less marked for distant metastasis than for regional relapse. The worst
prognosis categories were age older than 60 years, Breslow thickness more than 0.75 mm, MR  1,
presence of ulceration, presence of LVI, and regression  50%. Breslow thickness more than 0.75
mm, MR 1, presence of ulceration, and LVI (all P .001) were significantly associated with sentinel
node positivity. Age, MR, ulceration, LVI, regression, and sentinel node status were independent
predictors of survival and were used to construct a nomogram to predict 12-year overall survival. The
nomogram was well calibrated and had good discriminative ability (adjusted Harrell C statistic, 0.88).
Conclusion
Our findings suggest including LVI and regression as new prognostic factors in the melanoma
staging system. The nomogram appears useful for risk stratification in clinical management and for
recruiting patients to clinical trials.
J Clin Oncol 32:2479-2485. © 2014 by American Society of Clinical Oncology
INTRODUCTION
The incidence of cutaneous melanoma is increas-
ing.1 Most new cases are diagnosed when thin
(Breslow thickness  1 mm)2 and have favorable
prognoses. However, the 2009 American Joint
Committee onCancer (AJCC) emphasized the vari-
ability (85% to 99%) of 10-year survival for thin
melanoma.3 It is important therefore to identify
factors that influence prognosis.
Althoughthicknesshas longbeenrecognizedas
an importantprognostic factor forprimary localized
melanoma,4 various other factors have been pro-
posed as prognostic and suggested as stage indica-
tors.5 The current AJCC classification3 recognizes
two tumor-associated factors for thin melanomas:
mitotic rate (MR)andulceration.Low-risk (T1a)mel-
anomas arenonulcerated,with anMRof less thanone
mitosis per squaremillimeter; higher-risk (T1b)mela-
nomashave anMRofoneormoremitoses per square
millimeter, ulceration, or both. TheCommittee noted
that regional node metastasis was also an important
prognostic factor inearly-stagemelanomaandrecom-
mended sentinel node biopsy (SNB) in selected T1b
patients3 but did not have sufficient data to assess the
risk of occult nodalmicrometastases inT1patients.
Several studies have attempted to define the
role of SNB in thin melanoma and identify predic-
tors of sentinel node (SN) positivity, but findings
have been discordant.6-8 Recent guidelines,9,10 also
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 32  NUMBER 23  AUGUST 10 2014
© 2014 by American Society of Clinical Oncology 2479
from 130.192.119.156
Information downloaded from jco.ascopubs.org and provided by at Bibl.Centralizzata medicina e chirurgia on June 21, 2016
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
noting the lackof evidence to support routineSNBinT1patients, state
that SNB should be considered for selected high-risk patients.
These considerations highlight the variable risks associated
with T1 melanomas and the need to identify characteristics for
reliable risk stratification. The aim of this study was to identify
determinants of survival and predictors of SN status in a large
multicentric series of patients with thinmelanoma and construct a
nomogram predicting survival.
PATIENTS AND METHODS
Allpatientsdiagnosedand treated for a single thin (Breslow thickness 1.00mm
or less) primary melanoma from 1996 through 2004 at six European centers
were considered. Clinicopathologic data were retrieved from prospectively
maintained databases. Patients with satellites or metastases at diagnosis or
history of other cancer were excluded. Information retrieved comprised age,
sex, site (head and neck, trunk, limbs), Breslow thickness, MR, ulceration,
Clark level, presence or absence of lymphovascular invasion (LVI), regression,
and tumor-infiltrating lymphocytes (TILs). MR was expressed as number of
mitoses per square millimeter. TILs were classified as brisk, nonbrisk, or
absent. Regression was characterized as absent, partial ( 50% of the entire
primary lesion), or extensive ( 50%). LVI was defined as the presence of
melanoma cells within lymphatic or blood vessels.
After excluding 86 patients lost immediately after discharge and 42 pa-
tientswithmissing data, 2,243 patientswere included. All slideswere reviewed
independently by three pathologists (G.T., B.V., andC.L.) with disagreements
resolved by discussion.
Treatment consisted of diagnostic excision with 1-to 2-mm margins
followed by wider excision to achieve histologically confirmed 1-cmmargins
in healthy tissue. SNBwas offered to high-risk patients, forwhich criteriawere
Breslow thickness 0.75 to 1.00 mm, MR one or more mitoses per square
millimeter, presence of ulceration, presence of LVI, Clark level IV or V, and
extensive regression. The benefits and risks of SNB were discussed with pa-
tients. Some patients asked for and received SNB, although the risk of occult
nodalmetastasiswas low.AllpatientswithapositiveSNwereurged toundergo
node dissection.
Recurrences subsequent to definitive surgery were classified as local if
they developedwithin the primary scar, regional if theywere in-transit dermal
or subcutaneous metastases or in lymph nodes, and distant if they were
nonregional skin, nodal, or visceral metastases. All skin and node recurrences
were confirmed histologically.
The 2 orWilcoxon-Mann-Whitney test was used to determine signifi-
cant differences between stage T1a and T1b. Multivariable binary logistic
modelingwas used to explore propensity to performSNBaccording to year of
diagnosis, sex, age, tumor site, Breslow thickness, MR, ulceration, LVI, Clark
level, TILs, and regression. The response variable was zero if SNB was not
performed and 1 if it was performed.
In patients receiving SNB, the Wilcoxon-Mann-Whitney test (year of
diagnosis, age, Breslow thickness) or 2 test (other variables) assessed differ-
ences in the distribution of these variables between SN-negative and SN-
positive groups.
Themain study endpointwas overall survival (OS) calculated fromdate
of surgery for primary melanoma to date of death as a result of all causes or
censored at date of last follow-up in living patients. OS curves were estimated
byusing theKaplan-Meiermethod, and the log-rank testwasused to compare
subgroups. Additional end points were (crude cumulative incidences of) re-
gional relapse and distant metastasis, analyzed in a competing risks frame-
work11; time was calculated from date of definitive surgery to event date and
was censored at date of last follow-up in event-free patients. For regional
relapse, competing events were distant metastasis, death as a result of an
unrelated cause, local relapse, or secondmalignancy,whichever occurredfirst.
Fordistantmetastasis, competingeventswere regional relapse,deathasa result
of an unrelated cause, local relapse, and secondmalignancy.12 Because cumu-
lative incidences didnot reach 50%,wenoted values atmaximumobservation
timeandhalved them: times atwhichhalf themaximumcumulative incidence
occurred were consideredmedian times to events.
Multivariable Cox modeling was used to analyze OS. The proportional
hazards assumption was checked by using tests based on scaled Schoenfeld
residuals.13The covariates age,Breslow thickness,MR,ulceration, LVI, regres-
sion, SNB status, and SN status were investigated as prognostic factors. SNB
and SN status were initially represented by a three-level covariate (SNB not
done, SNB done/SN negative, SNB done/SN positive). However, the propor-
tional hazards assumption did not hold in that the hazard ratio for SNB not
doneversusSNBdone/SNnegative tended to increaseafter8years.UseofSNB
was therefore modeled as a stratification factor, and its interaction with SN
status was included as a covariate; the latter made it possible to estimate the
prognostic effect of SN-positive versus SN-negative disease, conditional on
SNB.SNBusedidnot interact significantlywithotherprognostic factors, sono
other interaction terms were included. A backward procedure based on the
Akaike information criterion14 was used to select covariates.
Thenomogram topredict 12-yearOSprobabilitywas developed from
the final Cox model. Nomogram performance was assessed by calibration
plot as an indicator of internal calibration and by the Harrell C statistic as
ameasure of discriminative ability.15 TheHarrell C statistic corresponds to
the area under the receiver operating characteristic curve; values 0.5 and 1,
respectively, indicate lack of discriminative ability and perfect discriminative
ability. A bootstrap procedure16 was adopted to adjust the C statistic estimate
for the optimism implicit in the use of sample data for model fitting and
variable selection.
In themultivariablemodels, yearofdiagnosis, age, andBreslowthickness
were continuous variables using three-knot restricted cubic splines.17 Re-
stricted cubic spline modeling has the advantage of avoiding categorization
and use of cutoffs (necessary to estimate Kaplan-Meier and crude cumulative
incidence curves) and of obtaining a flexible fit allowing the effects of contin-
uous variables not to be the same in everypart of the range. Thus, the covariate
values presented in theCoxmodel tables donot define categories but are exact
values (quartiles of the variable distribution). All categorical covariates were
modeled by using dummy variables. The analyses were carried out with SAS
(SAS Institute, Cary, NC) and R software (http://www.r-project.org/).
RESULTS
Patient and Disease Characteristics
Characteristics of the 2,243 patients, by stage, are summarized in
Table 1. Stage IA and IB patients did not differ regarding sex, age, site,
or presence of TILs. Of the T1a lesions, 45.2% were  0.50 mm
compared with 26.3% of T1b lesions, and 24.9% of T1a lesions were
more than 0.75mmcomparedwith 43.7%of T1b lesions. Among the
1,115 T1b patients, 982 (88.1%) had MR  1 and 530 (47.5%) had
ulceration. LVI was present in 19.1% of T1a patients and was present
in 43.6% of T1b patients. T1a patients were less likely than T1b
patients to have regression: less than 50% regression, 17.4% versus
21.9%; 50% regression, 10.3% versus 18.0%.
SNB
Overall, 794 patients (35.4%) received SNB (Table 2). The per-
centage of patients undergoing SNB (propensity) tended to decrease
with advancing age (from 36% to 28.8%). As expected, patients with
worse prognostic factors underwent SNBmore often. Thus, propen-
sity to undergo SNB increased with increasing Breslow thickness
(11.3% for  0.50 mm; 60.2% for  0.75 mm) and increasing MR
(from 28.1% to 44.8%).
Multivariable analysis showed that characteristics significantly
associated with propensity to undergo SNB were age, Breslow thick-
ness, ulceration, and LVI (all P  .001). Sixty-eight patients (8.6%)
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were SNpositive andunderwent regional nodal dissection. Increasing
Breslow thickness, high MR, ulceration, and LVI were significantly
associated with SN positivity (Table 2). The low number of patients
with a positive SN made reliable multivariable analysis of factors
associated with SN positivity impossible.
Relapse and Survival
Median follow-up was 124 months (interquartile range, 106 to
157 months). There were nine local relapses, 169 regional appear-
ances, and70distantmetastases as first event. Fifty-fivepatients devel-
oped another malignancy as first event, and six died (first event) of
causes unrelated to melanoma. Median times to local, regional, and
distant first events were 79, 78, and 107months, respectively.
Twelve-year estimatesof crude cumulative incidencesof regional
relapse and distant metastasis, in relation to age, Breslow thickness,
MR, ulceration, LVI, and regression, are provided in Table 3. Crude
cumulative incidence of local relapse was not estimated for low num-
bers of events. All factors listed in Table 3 significantly (all P .001)
influencedcrudecumulative incidencesof regional relapseanddistant
metastases. In general, incidence was lower and subgroup differences
Table 1. Characteristics of the 2,243 Patients With Thin Melanoma, According
to Stage at Diagnosis
Characteristic
Stage T1a Stage T1b
P
Whole
Series
No. % No. % No. %
Total No. of patients 1,128 50.3 1,115 49.7 NA 2,243 100.0
Year of diagnosis  .001
1996-1998 220 19.5 257 23.0 477 21.3
1999-2000 228 20.2 177 15.9 405 18.1
2001-2002 217 19.2 301 27.0 518 23.1
2003-2004 463 41.0 380 34.1 843 37.6
Sex .930
Female 612 54.3 608 54.5 1,220 54.4
Male 516 45.7 507 45.5 1,023 45.6
Age, years .767
Median 43.5 43 43
IQR 36-53 36.5-52 36-52
 40 445 39.5 424 38.0 869 38.7
 40 to  50 323 28.6 315 28.3 638 28.4
 50 to  60 228 20.2 236 21.2 464 20.7
 60 to  70 79 7.0 89 8.0 168 7.5
 70 53 4.7 51 4.6 104 4.6
Site .966
Head and neck 227 20.1 223 20.0 450 20.1
Trunk 470 41.7 460 41.3 930 41.5
Upper or lower limbs 431 38.2 432 38.7 863 38.5
Breslow thickness, mm  .001
Median 0.52 0.71 0.63
IQR 0.33-0.72 0.50-0.79 0.41-0.78
 0.50 510 45.2 293 26.3 803 35.8
 0.50 to  0.75 337 29.9 335 30.0 672 30.0
 0.75 to  1 281 24.9 487 43.7 768 34.2
Mitoses, No. per mm2  .001
 1 1,128 100.0 133 11.9 1,261 56.2
 1 0 0.0 982 88.1 982 43.8
Ulceration  .001
Absent 1,128 100.0 585 52.5 1,713 76.4
Present 0 0.0 530 47.5 530 23.6
Lymphovascular invasion  .001
Absent 912 80.9 629 56.4 1,541 68.7
Present 216 19.1 486 43.6 702 31.3
Clark level  .001
II or III 727 64.5 428 38.4 1,155 51.5
IV 401 35.5 687 61.6 1,088 48.5
Tumor-infiltrating
lymphocytes
.633
Absent 587 52.0 568 50.9 1,155 51.5
Present 541 48.0 547 49.1 1,088 48.5
Regression  .001
Absent 816 72.3 670 60.1 1,486 66.3
Present ( 50%) 196 17.4 244 21.9 440 19.6
Present ( 50%) 116 10.3 201 18.0 317 14.1
NOTE. Stage is according to the 2009 American Joint Committee on Cancer
classification.
Abbreviations: IQR, interquartile range; NA, not applicable.
2 or Wilcoxon-Mann-Whitney test, as appropriate.
Table 2. Demographic and Tumor Characteristics of the 794 Patients Who
Underwent SNB, and Association of Characteristics With SN Positivity
Characteristic
Undergoing
SNB Percent
of Whole
Series
Association
With SN
Positivity
No. % No. % P†
Sex .999
Female 414 52.1 33.9 35 8.5
Male 380 47.9 37.1 33 8.7
Age, years .059
 40 355 44.7 40.9 37 10.4
 40 to  50 188 23.7 29.5 16 8.5
 50 to  60 158 19.9 34.1 10 6.3
 60 to  70 63 7.9 37.5 4 6.3
 70 30 3.8 28.8 1 3.3
Site .993
Head and neck 155 19.5 34.4 13 8.4
Trunk 322 40.6 34.6 28 8.7
Upper or lower limbs 317 39.9 36.7 27 8.5
Breslow thickness, mm  .001
 0.50 91 11.5 11.3 3 3.3
 0.50 to  0.75 241 30.4 35.9 11 4.6
 0.75 462 58.2 60.2 54 11.7
Mitoses, No. per mm2  .001
 1 354 44.6 28.1 5 1.4
 1 440 55.4 44.8 63 14.3
Ulceration  .001
Absent 373 47.0 21.8 12 3.2
Present 421 53.0 79.4 56 13.3
Lymphovascular invasion  .001
Absent 436 54.9 28.3 24 5.5
Present 358 45.1 51.1 44 12.3
Clark level .962
II or III 370 46.6 32.0 31 8.4
IV 424 53.4 39.0 37 8.7
Tumor-infiltrating lymphocytes .945
Absent 353 44.5 30.6 31 8.8
Present 441 55.5 40.5 37 8.4
Regression .212
Absent 444 55.9 29.9 33 7.4
Present (extent  50%) 141 17.8 32.0 11 7.8
Present (extent  50%) 209 26.3 65.9 24 11.5
Abbreviations: SN, sentinel node; SNB, sentinel node biopsy.
Percentage of the total patients in each category.
†Wilcoxon-Mann-Whitney test (age and Breslow thickness evaluated as
continuous variables) and 2 test (other variables).
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less marked for distant metastasis than regional relapse. The poorer
prognosis categories were age older than 60 years, Breslow thickness
more than 0.75mm,MR 1, presence of ulceration, LVI, and regres-
sion 50%.
Regardingmortality, 231 patients died ofmelanoma and nine of
other causes; 12-year OS was 85.3% (95% CI, 83.4% to 87.2%). Re-
gional relapse anddistantmetastasis had amajor impact onmortality:
five of the nine who developed local relapse, 156 of the 169 who
developed regional relapse, and all 70 patients who developed distant
metastasis died of melanoma.
Table 3 also depicts (right-most two columns) 12-year OS esti-
mates according to age, Breslow thickness, MR, ulceration, LVI, and
regression. As for relapse, all factors investigated were significantly
associated with OS, and prognostic trends were similar.
In the Cox model analysis of OS, SNB use was included as a
stratification factor so that OS estimates could differ according to
whether or not SNB was performed. The following were evaluated:
age, Breslow thickness,MR, ulceration, LVI, regression, and SN status
(conditional to receiving SNB). The results of the final Coxmodel are
provided in Table 4. As a result of the selection procedure, Breslow
thickness was excluded, and the categories “regression absent” and
“regressionpresentwith extent less than50%”were fused.All remain-
ing factors were highly significant predictors of OS. The exclusion of
Breslow thickness from the model was the result of the strong associ-
ation between Breslow thickness and the other factors retained in the
model: greater thickness was associated with older age, MR  1,
presence of ulceration, LVI, and regression 50%.
The nomogrambased on the final Coxmodel is shown in Figure
1. By using the nomogram, 12-year OS probability can be estimated
from individual patient and tumor characteristics, conditional to SNB
or not.Negative prognostic factors contributed points so that increas-
ing total points were associated with increasingly worse prognosis. A
more detailed description of nomogram use is given in the Figure 1
legend. Notably, a given point score implies worse survival for a
patient not receiving SNB compared with a node-negative patient
receiving SNB. The discrepancy, usually in the 5% to 10% range,may
be explained by considering that unrecognized node-positive patients
Table 3. OS and Cumulative Incidence of Recurrence at 12 Years
Characteristic
Crude Cumulative Incidence
OSRegional Relapse Distant Metastasis
% 95% CI % 95% CI % 95% CI
Age, years
 40 1.2 0.6 to 2.3 2.1 1.2 to 3.5 96.8 95.3 to 98.2
 40 to  50 6.5 4.7 to 8.9 4.6 2.6 to 8.2 88.0 84.3 to 92.0
 50 to  60 7.7 5.5 to 10.7 6.2 4.1 to 9.4 82.9 78.7 to 87.4
 60 to  70 38.6 30.4 to 49.0 10.8 5.9 to 19.7 40.3 31.0 to 52.5
 70 37.6 28.9 to 48.9 5.7 2.4 to 13.6 43.3 32.0 to 58.6
Breslow thickness, mm
 0.50 1.1 0.5 to 2.3 1.9 1.0 to 3.7 96.8 95.2 to 98.5
 0.50 to  0.75 3.3 2.1 to 5.0 3.2 1.9 to 5.5 92.2 89.6 to 94.8
 0.75 to  1 19.8 17.1 to 23.0 7.0 5.2 to 9.4 70.8 67.0 to 74.9
Mitotic rate, No. per mm2
 1 1.8 1.1 to 2.8 2.4 1.5 to 3.7 95.3 93.8 to 96.8
 1 16.5 14.2 to 19.2 6.2 4.7 to 8.3 74.7 71.4 to 78.2
Ulceration
Absent 1.5 1.0 to 2.3 2.7 1.9 to 3.8 95.3 94.1 to 96.6
Present 29.4 25.6 to 33.8 8.7 6.2 to 12.1 57.7 52.5 to 63.3
Lymphovascular invasion
Absent 1.4 0.9 to 2.1 2.8 1.9 to 4.0 95.3 94.0 to 96.6
Present 23.1 20.0 to 26.8 7.1 5.1 to 9.8 65.6 61.1 to 70.3
Regression
Absent 1.8 1.3 to 2.7 3.4 2.4 to 4.9 94.1 92.6 to 95.7
Present ( 50%) 1.5 0.7 to 3.2 2.9 1.6 to 5.2 94.1 91.5 to 96.8
Present ( 50%) 44.7 39.4 to 50.7 8.1 5.4 to 12.0 48.5 42.7 to 55.0
Abbreviation: OS, overall survival.
Table 4. Multivariable Cox Regression Model of OS After Backward Selection
of Variables
Variable HR 95% CI P
Age 52 v 36 years† 3.88 2.69 to 5.59  .001
No. of mitoses per mm2  1 v  1 1.58 1.06 to 2.37 .026
Ulceration present v absent 3.81 2.51 to 5.80  .001
Lymphovascular invasion present v absent 1.81 1.24 to 2.65 .002
Regression  50% v absent or  50% 3.32 2.31 to 4.77  .001
SN status positive v negative‡ 2.97 1.86 to 4.76  .001
NOTE. Hazard ratio (HR) estimate is the risk of death for a given category or
value compared with the reference category or value. HR  1 indicates
greater risk than reference; HR  1 indicates lower risk than reference. The
larger the HR, the greater the association between the variable and risk of
death. CIs that do not include the value of one indicate a significant difference
for the category compared with reference.
Abbreviations: OS, overall survival; SN, sentinel node; SNB, sentinel
node biopsy.
Two-sided P value from Wald test.
†Third and first quartiles of age distribution, respectively.
‡Positive indicates undergoing SNB.
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are also present in the subset not receiving SNB, which in turn influ-
ences survival.
Thenomogramwas internally validatedby the calibrationplot in
Figure 2, and by computing the bootstrap-corrected Harrell C statis-
tic. The calibration plot suggests that the nomogram was well cali-
brated; predicted and observed survival were in good agreement
(circles lying almost directly on the reference line), with only minor
discrepancies between observed (circles) and corrected-for-optimism
(Xs) survival. A fairly high C statistic (0.88) was obtained, indicating
goodmodel discriminative ability.
DISCUSSION
Indications for treating clinically node-negative melanoma 1 mm
are continually being refined.3,9,10 One aim of this study was to inves-
tigate whether prognostic factors might predict regional lymph node
involvement. We found that MR 1, LVI in the primary tumor, or
both were significantly associated with SN positivity. Among patients
with metastatic SNs, MR  1 or LVI were significantly more likely
than MR less than 1 or no LVI (P  .001 in both cases). Previous
studies have investigated MR as a determinant of SN status in
smaller series. Kesmodel et al6 evaluated 181 patients with mela-
noma 1 mm undergoing SNB; they found that all patients with
positive SNs also had MRmore than 0. Sondak et al18 developed a
probabilisticmodel based on 419 patients withmelanomawho had
SNB. They found that patients younger than age 35 years with
tumors less than 1 mm had a substantial risk of a positive SN,
particularly if MR was high. Murali et al19 also found that LVI was
associated with SN positivity in melanomas  1.0 mm and con-
cluded that SNB should be considered in patients with lymphatic
permeation of melanoma at the primary site.
We also found that Breslow thickness ofmore than 0.75mmand
tumor ulceration were significantly related to SN positivity; however,
these variables are established independent predictors of SN status.3
Regarding regression, we found that the proportion of patients with a
positive SN increased in the order of no regression, less than 50%
regression, and 50% regression, but the association was not signif-
icant. Our findings therefore support the performance of SNB in
patients with one or more of the following: more than 0.75 mm
thickness,ulceration,MRoneormoreper squaremillimeter, andLVI.
Regarding outcomes, our findings provide support for the cur-
rent melanoma staging system3 by showing that high MR and ulcer-
ation were significantly predictive of poorer survival.
In our multivariable analysis, SN status emerged as an indepen-
dent factor predicting survival. However, SN status was not included
Points
0 10 20 30 40 50 60 70 80 90 100
Age (years)
15 20 25 30 35 40 45 50 55 60 70 80
Mitotic rate
(number/mm²) < 1
≥ 1
Ulceration
No
Yes
Lymphovascular
invasion No
Yes
Regression
No/< 50%
≥ 50%
SLN status
Neg
Pos
Total points
0 20 40 60 80 100 120 140 160 180 200
12-year OS, no SLN
0.010.050.10.20.30.40.50.60.70.80.90.950.99
12-year OS, SLN
0.010.050.10.20.30.40.50.60.70.80.90.950.99
Fig 1. Nomogram for 12-year overall sur-
vival (OS) in thin cutaneous melanoma. To
calculate the survival probability for a spe-
cific patient, locate patient age and draw a
line straight upward to the Points axis to
determine the score associated with that
age. Repeat the process for mitotic rate,
ulceration, lymphovascular invasion, re-
gression, and sentinel node (SN) status
(when sentinel node biopsy [SNB] was
performed), sum the scores for each fac-
tor, and locate this sum on the Total
Points axis. Then, depending on whether or
not SNB was performed, draw a line
straight down to the corresponding 12-year
OS axis to find the predicted OS probability.
SLN, sentinel lymph node.
0
Ac
tu
al
 O
S
Predicted OS
1.0
0.8
0.6
0.4
0.2
0.2 0.4 0.6 0.8 1.0
Fig 2. Calibration plots for internal validation of the overall survival (OS)
nomogram. Nomogram-predicted probabilities were stratified in subgroups and,
for each subgroup, the average predicted probability (x axis) was plotted against
the Kaplan-Meier probability observed in the present case series (y axis). The
95% CIs of the Kaplan-Meier estimates are indicated by vertical lines. The Xs
represent observed survival corrected for optimism in the same subgroup. The
dashed line is the reference line, indicating where an ideal nomogram would lie.
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as aprognostic factor in themost recentAJCCstaging system,3 and the
value of SN status has been debated. Han et al20 retrospectively evalu-
ated 271 patients with melanomas 1 mm and showed that OS did
not differ between patients with positive and negative SNs (P .53);
however, this studywas characterized by short follow-up (median 2.1
years). Venna et al21 examined SN status as a predictor of OS in 484
patients with thin melanoma, 34 of whom had a positive SN; by
multivariable analysis, SN status was the most powerful predictor
of survival (P  .009). That SN status predicts survival is in line
with the idea that regional lymph node involvement is an indicator
of the biologic aggressiveness of the disease and thus greater prob-
ability of extraregional spread and suggests that SN status can
contribute to improving the risk stratification in patients with
thin melanoma.
This study also found that LVI and extensive regression were
independent predictors of OS, again in contrast to the current mela-
noma staging system.3 Xu et al22 evaluated LVI as an independent
prognostic factor in 251 patients with primarymelanoma.Multivari-
able logistic regression for 10-yearmetastasis was used to define inde-
pendent prognostic factors, from which a prognostic tree was
developed to identify different risk groups. Among thin melanomas,
theprognostic tree identifiedT1bmelanomaswithLVIashavingpoor
prognoses. Egger et al23 investigated LVI in a cohort with primary
melanoma of all thicknesses. They found that, although LVI was not
an independentOSpredictor, it was a powerful predictor ofworseOS
among patients with evidence of regression.
In ourmultivariable analysis, extensive regression— 50% of
the entire lesion—was strongly associated with poor OS. Some
studies have reported similar findings24,25; however, other studies
have reported that regression has no effect on prognosis.26,27 It is
possible that thin melanomas with regression are actually thicker,
but that the measured thickness of residual melanoma in the re-
gressed tumor is an underestimate of original thickness. In such
cases, the metastatic potential of the tumor might be better pre-
dicted by the original thickness rather than the thickness of residual
melanoma in the regressed tumor, thereby explaining the associa-
tion of regressionwithmetastasis. The effect of regression inmask-
ing thickness is likely to be proportionally greater in thin
melanomas, a hypothesis supported by Massi et al,24 who found
that tumor thickness and regression thickness were strong inde-
pendent predictors of progression in thin melanomas.
On the basis of the hypothesis that the greater the extent of
regression, the greater the underestimate of true thickness, we divided
thin melanomas into two groups: one without regression or not ex-
ceeding 50%, the other with regression 50%.We found that in the
latter group, regression was a reliable prognostic variable.
Because our series was large with long follow-up and strong
prognosticassociationswereobserved,wedecided todevelopanomo-
gram to predict 12-year OS. We propose the nomogram as a useful
predictor of survival in individual patients and as a useful tool for risk
stratification in clinical studies. It is noteworthy that the nomogram
includes age as an important determinant of prognosis, because older
age at diagnosis was significantly related to a poorer outcome. Other
recent studies have also reported that older age was significantly asso-
ciated with lower survival.28,29
Another interesting finding of our study was that most recur-
rences developed more than 5 years after diagnosis, and often 8 to 10
years later. In general, disease recurrence 10 years after initial treat-
ment is rare; however, late recurrences are known, and they seem
more common in patients with thin primary lesions.30
To conclude, we have found that LVI and extensive regression
are independent predictors of survival in patients with thin mela-
nomas, andwe propose that these variables should be included in a
revised melanoma staging system. We have also shown that SN
status is an independent predictor of survival and that highMRand
presence of LVI predict SN positivity, so their presence should
suggest performing an SNB. In the absence of data from random-
ized controlled trials, our retrospective data provide rational bases
for making treatment decisions in patients with thin melanoma by
identifying those at relatively high risk of dying from their disease
who may benefit from more aggressive treatments and long-term
follow-up. Nevertheless, further studies on independent series are
advisable to assess the reproducibility of our results, externally
validate the nomogram, and confirm its utility for decision mak-
ing.
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